STU:RV6's ROA % is ranked worse than 51.87% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.11
vs STU:RV6: -2.46
Charles River Laboratories International (STU:RV6) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Charles River Laboratories International ROA % Related Terms
Charles River Laboratories International ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International ROA % Chart
Charles River Laboratories International Annual Data
For the Diagnostics & Research subindustry, Charles River Laboratories International's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International ROA % vs Medical Diagnostics & Research Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Charles River Laboratories International (STU:RV6) has a ROA % of -0.80% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Charles River Laboratories International and its competitors. According to the industry distribution chart, Charles River Laboratories International ranks #111 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 51.9%.
Is Charles River Laboratories International's ROA % too high?
Charles River Laboratories International's current ROA % is -0.80%. Based on the distribution chart, Charles River Laboratories International ranks #111 out of 214 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Charles River Laboratories International has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's ROA % compare to RVTY and QGEN?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #111 out of 214 companies for ROA %. This places Charles River Laboratories International in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Diagnostics & Research company?
A good ROA % depends on the Medical Diagnostics & Research industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Charles River Laboratories International and its competitors. Charles River Laboratories International's current ROA % is -0.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (STU:RV6) is currently considered Modestly Overvalued. The stock's GF Value™ is €169.03, compared to a current price of €195.85 — trading 15.9% above its estimated fair value. The current ROA % is -0.80%. Charles River Laboratories International's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Charles River Laboratories International (STU:RV6), the current ROA % is -0.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (STU:RV6) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of €195.85 is trading 15.9% above its estimated GF Value™ of €169.03.
GuruFocus considers Charles River Laboratories International to be Modestly Overvalued.
Key valuation signals for STU:RV6:
ROA %: -0.80%
GF Value™: €169.03 vs. price of €195.85 (15.9% above fair value)
No single metric tells the full story. See the STU:RV6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories International Business Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
70GF Score
Get the complete analysis for STU:RV6
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RV6 has been successfully added to your 
